Teva has previously launched its generic budesonide respules in the US. The agreement releases Teva for all past US sales of its generic budesonide respules and provides that any product already shipped by Teva will remain in the market to be further distributed and dispensed.
Teva will not resume shipping additional units of its budesonide respules until December 15, 2009 (or earlier based on certain contingencies) pursuant to an exclusive license for which Teva will pay AstraZeneca an undisclosed royalty.